Murwere Wekutanga Akarapwa Mukutongwa kwePost-Surgical Chronic Rhinosinusitis

Lyra Therapeutics, Inc. nhasi yakazivisa kuti murwere wekutanga akabatwa muChikamu 1 / chikamu chisina-randomized chePhase 2 BEACON kliniki yekuedza yeLYR-220 muvarwere vakuru vane chirwere chisingaperi cherhinosinusitis (CRS) avo vakambovhiyiwa sinus. LYR-220 yakanyatsogadzirirwa kuendesa mwedzi mitanhatu yekuenderera mberi kwemishonga yekurwisa-kuzvimba mune inodzorwa uye inowirirana fashoni kune sinonasal ndima kune mamirioni evarwere veCRS vanoramba vachida kurapwa kunyangwe vambovhiyiwa. Mibairo yepamusoro kubva Chikamu chekutanga chechikamu chechipiri BEACON muyedzo inotarisirwa kupera kwegore.      

"Isu tine mashoma uye kazhinji asingashande ekurapa maitiro ekudzikisa zvinoramba zvichiitika, zvinoremedza zviratidzo muvarwere veCRS zvakambovhiyiwa," akadaro Anders Cervin, MD, PhD, Muzvinafundo Sachigaro muOtolaryngology paCentre for Clinical Research, Royal Brisbane & Women's Hospital. Campus, Herston, muQueensland, Australia, uye Principal Investigator muchidzidzo cheBEACON. "LYR-220 inogona kumiririra kufambira mberi kwakanaka mukutarisira varwere vasina kuchengetedzwa, vazhinji vacho vasina nzira dzakatenderwa dzekurapa zvinodhaka."

Iyo Phase 2 BEACON muyedzo ndeye inodzorwa parallel-boka chidzidzo chekuongorora kuchengetedzwa, kushivirira, pharmacokinetics, uye kugona kuenzanisa maviri magadzirirwo eLYR-220 (7500µg MF) matrix kudzora, mukati memavhiki makumi maviri nemana, mune angangoita makumi manomwe ane zviratidzo CRS zvidzidzo vakambovhiyiwa bilateral sinus. Chikamu 24 ndechisina-randomized, yakavhurika-label kudzidza ichiongorora kugona kwekuiswa kwekugadzirisa maitiro, nepo Chikamu 70 chinenge chiri murwere-akapofumadzwa, 1: 2: 1 randomized ongororo yemagadzirirwo maviri achipesana nesham control. Iyo Kambani inotarisira kupedzisa kunyoresa kune yakazara Phase 1 BEACON kuyedza kupera kwegore.

"Ichi chinomiririra chiitiko chakakosha kuLyra apo isu tinosimudzira yedu yechipiri CRS chigadzirwa mukwikwidzi wedanho rekupedzisira, zvichitiisa isu kuti tive vekutanga kupa mhinduro kune yakazara yakazara varwere veCRS vanorapwa nanachiremba veENT," akadaro Maria Palasis, PhD. , Mutungamiri uye Mukuru Mukuru weLyra Therapeutics. "Tinotarisira kusimudzira LYR-220 kuburikidza nekiriniki uye nekusimudzira nzira yeLYR-210, kurapa kwedu kwekuferefeta kune varwere veCRS vane kuvhiyiwa-naïve anatomy, parizvino mune yakakosha Phase 3 kuyedzwa (ENLIGHTEN I), kune ramangwana regiyori mafaera. ”